Missouri Roundup Cancer Claims After the Supreme Court’s FIFRA Preemption Ruling: What Just Happened, What Survives, and What to Do Right Now
You heard the news and your stomach dropped. The Supreme Court sided with Bayer. The headline said something about federal law blocking state lawsuits over Roundup warnings, and the first thought that hit you was: my case is over. Maybe you have non-Hodgkin’s lymphoma and you used Roundup for years. Maybe your father did, and he didn’t survive it. Maybe you have a lawyer already, and the phone hasn’t rung yet, and the silence is its own kind of terror.
We are going to tell you the truth about what this ruling means — and what it does not mean — because the truth is more complicated and more useful than the headline. The Supreme Court did close a door. It did not close the building. The $7.3 billion settlement that a Missouri state court preliminarily approved in March 2026 was built specifically to provide compensation regardless of how the Supreme Court ruled, and it is still standing. Legal theories that do not depend on the warning label are still under active development. And the question that matters most — whether you can still pursue compensation — has a more nuanced answer than a seven-word headline can carry.
We are Attorney911 — The Manginello Law Firm, PLLC. We are trial attorneys who take toxic tort and chemical exposure cases in Missouri and across the country. Ralph Manginello has spent 27-plus years in courtrooms, including federal court. Lupe Peña spent years inside a national insurance-defense firm before crossing to this side of the table — he knows how the companies on the other end price claims, delay them, and design settlements to close cases cheaply. We work on contingency: 33.33% before trial, 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free. And the call is answered by a live person, twenty-four hours a day, at 1-888-ATTY-911.
What follows is the full picture — the ruling, the law, the medicine, the money, the evidence, the playbook the other side is already running, and the concrete steps that matter right now.
What the Ruling Eliminates — and Why Failure-to-Warn Was the Primary Theory
The failure-to-warn theory was the engine of the Roundup litigation. It was the theory that produced the jury verdicts — including the $1 million-plus verdict in the Missouri case that reached the Supreme Court. The theory was straightforward: Monsanto knew or should have known that glyphosate was associated with cancer risk, and it failed to warn users on the product label. The jury would hear about the International Agency for Research on Cancer’s 2015 classification of glyphosate as “probably carcinogenic to humans” (Group 2A), about internal Monsanto documents discussing the science, and about the gap between what the company knew and what the label said. Then the jury would decide whether the failure to warn caused the plaintiff’s cancer.
That theory is now preempted. The Supreme Court’s logic is that the EPA’s label determination is itself a federal requirement — and under FIFRA’s express preemption provision, states cannot impose labeling requirements that are different from or additional to what the EPA has approved. A state tort suit that would require Monsanto to add a cancer warning is, in the Court’s view, imposing a state labeling requirement that conflicts with the federal one.
This eliminates the failure-to-warn claim not just in Missouri but nationwide. It means that any pending Roundup case that is built solely on a failure-to-warn theory faces a preemption motion that will likely succeed. And it means that future Roundup claims cannot be pleaded on a failure-to-warn basis.
But here is what a generalist misses and what we want you to understand: the failure-to-warn theory was the primary theory, but it was not the only theory. And the ruling’s reasoning — that the claim would require a label change the EPA rejected — creates a specific boundary. Claims that do NOT require a label change may survive. That boundary is where the next chapter of this litigation is being written right now.
The $7.3 Billion Settlement: Your Primary and Most Certain Recovery Vehicle
While the Supreme Court was deciding the preemption question, Bayer was negotiating a settlement. In March 2026, a Missouri state circuit court granted preliminary approval to Bayer’s proposed $7.3 billion national settlement — a figure class counsel has described as $7.25 billion. This settlement was designed specifically to provide compensation to Roundup cancer victims regardless of how the Supreme Court ruled on FIFRA preemption.
The proposed class counsel, quoted in the public reporting, said it plainly: “This Supreme Court ruling wrongly slams the courthouse door on Americans sickened by pesticides and underscores why we negotiated a $7.25 billion settlement that guarantees compensation to Roundup victims regardless of today’s decision.”
The settlement provides a structured recovery mechanism with compensation tiered by diagnosis severity, exposure duration, and age at diagnosis. Based on the case value framework in our analysis, individual settlement-class participants can expect compensation ranging from approximately $25,000 on the low end to $500,000 or more on the high end, depending on where they fall in the tiering structure.
Here is what you need to understand about the settlement right now:
The settlement is not final. Preliminary approval was granted in March 2026. Final approval requires a fairness hearing, notice to class members, an opportunity for class members to object or opt out, and a final order from the court. Settlement-objector proceedings can delay or alter final approval. The timeline from preliminary to final approval can stretch over months.
You may need to act within specific deadlines. Class members must file claims or make elections within specified claim-filing or opt-out windows. These windows may close before you realize the ruling’s impact on individual litigation. If you miss the window, you may lose your right to participate in the settlement or to pursue an individual claim outside it.
You have a choice to make. You can participate in the class settlement and accept the compensation tier assigned to your claim. Or you can opt out and pursue an individual case — but after the SCOTUS ruling, an individual case faces the preemption barrier on failure-to-warn and the uncertainty of surviving theories. The settlement provides a guaranteed recovery path; individual litigation provides a higher potential ceiling but with significantly greater risk and motion practice.
The settlement does not require you to prove failure-to-warn. The settlement compensation is structured around your diagnosis, your exposure history, and your age — not around which legal theory you would have pursued at trial. This is precisely why the settlement was designed: to provide recovery independent of the legal theory that the Supreme Court just preempted.
This is the decision that matters most right now, and it has a deadline. If you have a Roundup cancer claim — whether you already have a lawyer, whether you have a pending lawsuit, or whether you have never filed anything — you need to understand your settlement options before the windows close. That conversation is free. The number is 1-888-ATTY-911.
Justice Thomas’s Concurrence: The Constitutional Challenge to FIFRA Itself
Justice Clarence Thomas wrote separately, concurring with the majority’s preemption holding but raising a deeper question: whether FIFRA itself is constitutional.
Thomas argued that FIFRA likely exceeds Congress’s authority under the Commerce Clause, which authorizes Congress to regulate commerce among the states but not agriculture or manufacturing activities that are separate from commerce. FIFRA is a “comprehensive regulatory statute” that regulates the use and sale of pesticides, including pesticides produced and sold in intrastate commerce — activity Thomas argued is outside the Commerce Clause’s reach.
Thomas’s argument goes further than the preemption question. He identifies what he sees as the root problem: the modern administrative state, in which federal agencies exercise core legislative power through schemes that may exceed even Congress’s own constitutional authority. If agencies were not exercising that power, Thomas wrote, there would be “far less occasion to address conflicts between agency actions and state law that the Constitution’s framers would not have envisioned.”
What this means for Roundup litigation: Thomas’s concurrence signals that future constitutional challenges to FIFRA’s framework are possible. If FIFRA itself is unconstitutional — or if its application to purely intrastate pesticide activity is unconstitutional — then the preemption shield it provides could eventually collapse. This is a long-game argument, not an immediate path to recovery, but it tells you that the legal architecture the majority relied on is not universally accepted even on the Supreme Court itself.
The Defendant: Bayer AG and Monsanto Company — Corporate Structure and Deep Pockets
The entity you are pursuing is not a single company. It is a corporate family, and understanding that family matters for recovery.
Bayer AG is the German pharmaceutical and life sciences conglomerate that acquired Monsanto in 2018 for approximately $63 billion. When Bayer bought Monsanto, it assumed the Roundup litigation liability — tens of thousands of claims alleging that glyphosate-based herbicides caused cancer. Bayer has led settlement negotiations, managed the multi-pronged litigation strategy, and is the deep-pocket parent with global assets and direct involvement in litigation decisions.
Monsanto Company is the original designer, manufacturer, tester, marketer, and distributor of Roundup. It held the corporate knowledge of glyphosate toxicology research, controlled the labeling decisions submitted to EPA for registration approval, and is the entity named in the lawsuits. Monsanto is now a wholly-owned subsidiary of Bayer. The caption defendant in the litigation is still “Monsanto” — but the parent standing behind it, with the balance sheet and the global insurance tower, is Bayer.
This corporate structure matters for two reasons. First, it identifies where the money is. Bayer AG is a global pharmaceutical giant with the resources to fund a $7.3 billion settlement and to litigate aggressively against surviving claims. The coverage tower behind Roundup litigation is not a single insurance policy — it is a combination of Bayer’s self-insured retention, layered commercial coverage, and the corporate balance sheet itself. Second, it matters for strategy. Bayer’s motivation is containment — closing the litigation chapter, finalizing the class settlement, and moving past a decade of legal battles. That motivation is leverage for claimants who understand the timeline and the settlement structure.
Bayer said in its public statement that the court’s decision “should help significantly contain the Roundup litigation after nearly a decade of legal battles” and that “the ruling should result in the dismissal of current warning-based claims and bar future failure-to-warn claims.” The company also said it “will continue to pursue final approval of the class settlement and other elements of its multi-pronged strategy to contain the Roundup litigation.” Read that statement carefully: Bayer’s own framing is about containment, not victory. They want to close the book. The settlement is how they plan to do it. And your participation in that settlement — or your decision to opt out and pursue a non-preempted individual theory — is the choice that determines what your recovery looks like.
The Evidence Clock: What Records Exist, Who Holds Them, and How Fast They Can Die
The evidence in a Roundup cancer case falls into several categories, and each has its own preservation urgency. The SCOTUS ruling did not change the evidence landscape — but it changed which evidence matters most, because the surviving theories depend on different proof than the now-preempted failure-to-warn claim.
Your medical records — the NHL diagnosis, pathology, treatment history, and ongoing monitoring — establish the injury and the damages. These are held by your treating physicians, hospitals, and oncology clinics. Standard medical record retention applies, but records become harder to obtain as providers archive or purge older files. If you were diagnosed years ago, obtain your complete medical record now — including the original pathology report, the staging workup, all treatment summaries, and the imaging reports. These are the documents that prove your injury and its severity, and they are the documents the settlement claims process will require.
Your Roundup purchase and usage records — receipts, product containers, work history documentation, agricultural application logs — establish the exposure duration, frequency, and dose. These are critical for specific causation expert testimony linking your individual Roundup use to your NHL. Personal records degrade quickly. Product containers get discarded. Receipts fade or are thrown away. Witness memory of usage patterns fades over the twenty-year exposure window typical in these cases. If you have any physical evidence — old Roundup containers, purchase receipts, employment records showing herbicide application duties — preserve them immediately. Photograph them. Store them safely.
Internal Monsanto/Bayer research documents — emails, memos, and communications regarding glyphosate carcinogenicity and the IARC classification — support the non-preempted fraudulent concealment and negligence-in-testing theories. These documents demonstrate corporate knowledge of cancer risks independent of labeling decisions. Corporate document retention policies and existing litigation holds should preserve these, but document destruction or privilege designation may limit accessibility over time. Many of these documents were previously produced in discovery in earlier Roundup cases; their availability depends on ongoing litigation holds and protective order provisions.
EPA registration correspondence and labeling determination files — establish what the EPA reviewed and what warnings it determined were or were not necessary. These are central to preemption analysis and to identifying any gap between the EPA’s review and Monsanto’s knowledge. Federal agency records are maintained under administrative retention schedules and are accessible through Freedom of Information Act requests, though processing delays and redactions are common.
Internal communications regarding scientific publication influence — evidence of ghostwriting, consultant relationships, or coordinated efforts to shape the scientific literature — support punitive damages on fraudulent concealment theories that may survive preemption. These were previously produced in discovery; availability depends on ongoing litigation holds and protective order provisions.
The IARC monograph on glyphosate (Volume 112) and supporting scientific literature on the glyphosate-NHL association — these provide the general causation foundation. The IARC classified glyphosate as probably carcinogenic (Group 2A) in 2015. These materials are publicly available and permanent; there is no preservation urgency, but they must be curated for expert report development.
The fastest-dying evidence is your personal evidence — the receipts, the containers, the witness memories. If you used Roundup for years and developed NHL, the single most important thing you can do today is write down everything you remember about your Roundup use: when you started, when you stopped, how often you used it, where you bought it, what size containers, what you used it for (lawn care, farming, commercial application, gardening), and who might have seen you use it. This document is the foundation of your exposure proof, and memory fades faster than you think.
The Playbook: What Bayer’s Lawyers and Claims Administrators Are Doing Right Now
The other side has a playbook, and it is already running. Understanding it is your first layer of protection.
Play 1: The preemption motion. Bayer’s lawyers will file motions to dismiss failure-to-warn claims in every pending Roundup case, citing the Supreme Court’s ruling. The motion will argue that the ruling bars not just failure-to-warn but any claim that implicitly depends on the adequacy of the label. The counter: carefully pleaded non-warning theories — design defect, fraudulent concealment, negligence in testing — are independent of labeling and should survive. But this fight takes time, costs money, and produces inconsistent early results across jurisdictions. Bayer is counting on the motion pressure to push claimants into the settlement.
Play 2: The “EPA said it’s safe” narrative. Bayer will lean on the EPA’s determination that no cancer warning was needed as evidence that the product is safe. The counter: the IARC’s Group 2A classification, the scientific literature on glyphosate-NHL association, and the evidence of Monsanto’s influence on the regulatory process all undermine the “EPA said it’s safe” narrative. But the counter requires expert testimony and documentary evidence — resources that individual claimants may not have outside of coordinated litigation.
Play 3: The settlement squeeze. Bayer’s public statement said the ruling “should result in the dismissal of current warning-based claims” and that the company will “continue to pursue final approval of the class settlement.” The strategy is clear: use the ruling to make individual litigation look impossible, drive claimants into the settlement class, and close the litigation chapter. The counter: the settlement was designed to compensate regardless of the ruling, which means the ruling does not reduce your settlement value — it confirms why the settlement exists. But the settlement squeeze works on people who do not understand this, who hear the headline and assume their case is dead, and who either drop their claims or accept a lower tier than their diagnosis warrants.
Play 4: The general causation attack. Even on surviving theories, Bayer will challenge the scientific link between glyphosate and NHL. The defense will hire epidemiologists and toxicologists to argue that the evidence is insufficient, that the IARC classification is an outlier, and that the plaintiff’s NHL was idiopathic — meaning it came from nowhere, not from Roundup. The counter: the IARC monograph, the published epidemiological evidence, and a qualified oncology and toxicology expert team that can bridge general causation (glyphosate can cause NHL) and specific causation (this plaintiff’s NHL was more likely than not caused by their glyphosate exposure).
Play 5: The specific causation attack. Bayer will argue that even if glyphosate can cause NHL, this particular plaintiff cannot prove that their NHL was caused by Roundup rather than something else. NHL has multiple known and suspected causes, and the defense will exploit every alternative explanation. The counter: a detailed exposure reconstruction — how long, how often, what dose — combined with the plaintiff’s medical history excluding or discounting alternative causes, and expert testimony applying the dose-response literature to the individual’s exposure profile.
Play 6: The statute of limitations defense. Bayer will argue that the clock ran out — that the plaintiff knew or should have known about the connection between Roundup and cancer long before they filed. The counter: the discovery rule. For many plaintiffs, the connection between their NHL diagnosis and decades-old Roundup use was not apparent until the IARC classification in 2015, the media coverage of the Roundup litigation, or a lawyer’s outreach. The accrual date — when the clock starts — is a fact-specific question that depends on what the plaintiff knew and when they knew it.
Wrongful Death: If You Lost Someone to NHL After Roundup Exposure
If your spouse, parent, or child developed non-Hodgkin’s lymphoma after years of Roundup use and did not survive, the legal picture includes an additional layer. Wrongful death claims in Missouri are governed by the state’s wrongful death statute, which provides a separate limitations period — typically three years — and defines who may bring the claim (the surviving spouse, children, or parents, in a statutory priority order) and what damages are recoverable (the financial support the deceased would have provided, the companionship and guidance lost, the pain and suffering the deceased experienced before death, and in some cases punitive damages).
The SCOTUS preemption ruling applies to wrongful death failure-to-warn claims just as it applies to personal injury failure-to-warn claims — the theory is preempted. But the non-preempted theories (design defect, fraudulent concealment, negligence in testing) are available in a wrongful death context as well. And the settlement class includes claims for deceased Roundup users — the settlement tiering accounts for this, and a wrongful death claim may fall into a different compensation category than a personal injury claim.
The statute of limitations for wrongful death is a particular concern. The three-year clock generally starts from the date of death, not the date of exposure or the date of diagnosis. If your loved one died more than three years ago, the wrongful death claim may be time-barred — though the discovery rule and other tolling doctrines may apply in limited circumstances. If the death was recent, the clock is running now. This is a deadline that cannot be extended by waiting, and it is a reason to call today rather than tomorrow.
Who We Are: Ralph Manginello and Lupe Peña
Ralph Manginello is the Managing Partner of Attorney911 — The Manginello Law Firm, PLLC. He has been licensed in Texas since November 6, 1998 — 27-plus years of trial practice — and is admitted to the U.S. District Court for the Southern District of Texas, including federal court. He was a journalist before he was a lawyer, which means he asks questions for a living and writes to be understood. He has recovered more than $50 million for clients across his career, including a $5 million-plus brain-injury settlement, a $3.8 million-plus amputation settlement, and a $2.5 million-plus truck-crash recovery. He is the lead counsel in the active $10 million-plus Bermudez v. Pi Kappa Phi / University of Houston hazing lawsuit filed in Harris County in November 2025. He hates losing more than he likes winning, and the difference shows up in the preparation. You can read more about Ralph here.
Lupe Peña is an Associate Attorney, licensed in Texas since December 2012, and admitted to the U.S. District Court for the Southern District of Texas. Before he joined this firm, Lupe spent years inside a national insurance-defense firm — the rooms where adjusters and their software decide how to deny, delay, and devalue claims exactly like yours. He knows how Colossus values injuries, how reserves are set in the first 48 hours before the real injuries are diagnosed, how IME doctors are selected, and how the quick settlement check arrives with a release printed on the back before the MRI results do. He now uses that knowledge for injured clients. Lupe is fluent in Spanish and conducts full consultations in Spanish without an interpreter. You can read more about Lupe here.
We take cases in Missouri working with local counsel as required. We do not claim an office in Missouri. We do not claim a Missouri bar admission. What we claim is the experience, the resources, and the willingness to fight for people who have been injured by products that were supposed to be safe — and the knowledge of how the other side operates, because one of us used to be on that side.
Past results depend on the facts of each case and do not guarantee future outcomes.
The Call That Costs Nothing and May Change Everything
If you or someone you love developed non-Hodgkin’s lymphoma after years of using Roundup, the Supreme Court’s ruling changed the legal landscape — but it did not erase your right to seek compensation. The $7.3 billion settlement is still standing. Non-preempted legal theories are still under development. The evidence that connects your cancer to your exposure is still in your medical records and your personal history. And the deadline — whether it is the settlement claim window, the statute of limitations, or the opt-out election period — is running right now, while you read this.
We work on contingency. We do not get paid unless we win your case. The consultation is free — not a sales call, not a screening, a real conversation with a real attorney who will tell you honestly where you stand and what your options are. If we are not the right fit, we will tell you. If your case has a path forward through the settlement or through a non-preempted theory, we will tell you that too — and what the next steps look like.
The call is answered by a live person, twenty-four hours a day. 1-888-ATTY-911. Hablamos Español. Contact us.
The Supreme Court closed a door. It did not close the building. Let’s find out which doors are still open for you.